Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease
- 25 January 2005
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 64 (2), 216-223
- https://doi.org/10.1212/01.wnl.0000149637.70961.4c
Abstract
To compare daytime intraduodenal levodopa/carbidopa infusion as monotherapy with individually optimized conventional combination therapies in patients with advanced Parkinson disease (PD) for motor fluctuations and quality of life (QoL). Twenty-four patients with motor fluctuations and dyskinesia were studied in a randomized crossover design to compare individualized conventional treatment and intraduodenal infusion of a levodopa/carbidopa gel for 3 + 3 weeks. Video scoring of motor function was assessed by blinded assessors on a global Treatment Response Scale from -3 to 0 to +3 (from severe "off" to "on" to "on" with severe dyskinesia). Patient self-assessment of motor performance and QoL was done using an electronic diary. Median percentage of ratings in a functional "on" interval (-1 to +1) was increased from 81 to 100% by infusion therapy (p < 0.01). This improvement was accompanied by a decrease in "off" state (p < 0.01) and no increase in dyskinesia. Median Unified Parkinson's Disease Rating Scale score decreased from 53 to 35 in favor of infusion (p < 0.05). QoL was improved, using the two instruments: Parkinson's Disease Questionnaire-39 and 15D Quality of Life Instrument (p < 0.01). Adverse events were similar for both treatment strategies. Continuous intraduodenal infusion of the levodopa/carbidopa enteral gel as monotherapy is safe and clinically superior to a number of individually optimized combinations of conventional oral and subcutaneous medications in patients with motor fluctuations. Intraduodenal infusion of levodopa offers an important alternative in treating patients with advanced Parkinson disease.Keywords
This publication has 22 references indexed in Scilit:
- Wireless real‐time electronic data capture for self‐assessment of motor function and quality of life in Parkinson's diseaseMovement Disorders, 2003
- Five-Year Follow-up of Bilateral Stimulation of the Subthalamic Nucleus in Advanced Parkinson's DiseaseNew England Journal of Medicine, 2003
- Optimizing Levodopa Pharmacokinetics: Intestinal Infusion Versus Oral Sustained-Release TabletsClinical Neuropharmacology, 2003
- Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: Long‐term follow‐up study of 64 patientsMovement Disorders, 2002
- Levodopa Pharmacokinetics and Motor Performance During Activities of Daily Living in Patients With Parkinson's Disease on Individual Drug CombinationsClinical Neuropharmacology, 2002
- EditorialMovement Disorders, 2002
- Deep-Brain Stimulation of the Subthalamic Nucleus or the Pars Interna of the Globus Pallidus in Parkinson's DiseaseNew England Journal of Medicine, 2001
- Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's diseaseMovement Disorders, 1998
- Continuous Duodenal Infusions of LevodopaClinical Neuropharmacology, 1988
- Duodenal delivery of levodopa for on‐off fluctuations in parkinsonism: Preliminary observationsAnnals of Neurology, 1986